CDK9 As a New Therapeutic Vulnerability for Ibrutinib Resistance Mantle Cell Lymphoma (MCL)

被引：0
|
作者：
Wang, Michelle
Zhao, Xiaohong
Jiang, Huijuan
Yan, Joy Catherine
Sotomayor, Eduardo
Shain, Kenneth H.
Shah, Bijal
Tao, Jianguo
机构：
来源：
BLOOD | 2020年 / 136卷
关键词：
D O I：
10.1182/blood-2020-141386
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：2
相关论文
共 50 条
  • [1] CDK9 Inhibition Overcomes Ibrutinib Resistance in Mantle Cell Lymphoma (MCL)
    Roleder, Carly
    Dominguez, Edward C.
    Chen, Andrew
    Ball, Brian J.
    Danilova, Olga
    Danilov, Alexey
    BLOOD, 2023, 142
  • [2] The Selective CDK9 Inhibitor VIP152 Overcame Therapeutic Resistance in Mantle Cell Lymphoma
    Lee, William
    Jiang, Vivian Changying
    Zhang, Tianci
    Yan, Fangfang
    Cai, Qingsong
    McIntosh, Joseph
    Liu, Yang
    Wang, Michael L.
    BLOOD, 2023, 142
  • [3] Targeting Transcription Checkpoint Using a Novel CDK9 Inhibitor in Mantle Cell Lymphoma
    Lian, Junwei
    Xue, Yu
    Jordan, Alexa A.
    McIntosh, Joseph
    Liu, Yang
    Wang, Michael
    Zhou, Jia
    Jiang, Vivian Changying
    BLOOD, 2020, 136
  • [4] CDK9 Inhibition by Dinaciclib Is a Therapeutic Vulnerability in Epithelioid Hemangioendothelioma
    Pobbati, Ajaybabu V.
    Burtscher, Ashley
    Rajaram Siva, Nandini
    Hallett, Andrea
    Romigh, Todd
    Che, Kepeng
    Zhao, Bin
    Coker, Jesse A.
    Wang, Nancy
    Stauffer, Shaun R.
    Rubin, Brian P.
    CLINICAL CANCER RESEARCH, 2024, 30 (18) : 4179 - 4189
  • [5] The CDK9 inhibitor enitociclib overcomes resistance to BTK inhibition and CAR-T therapy in mantle cell lymphoma
    Jiang, Vivian
    Lee, William
    Zhang, Tianci
    Jordan, Alexa
    Yan, Fangfang
    Cai, Qingsong
    Mcintosh, Joseph
    Vargas, Jovanny
    Liu, Yang
    Wang, Michael
    BIOMARKER RESEARCH, 2024, 12 (01)
  • [6] Targeting Kinome Reprogramming for Overcoming Ibrutinib-Resistance (IR) in Mantle Cell Lymphoma (MCL)
    Zhao, Xiaohong
    Jiang, Huijuan
    Wang, Michelle
    Li, Tao
    Gao, Jing
    Lwin, Tint
    Ren, Yuan
    Sotomayor, Eduardo
    Shah, Bijal D.
    Tao, Jianguo
    BLOOD, 2018, 132
  • [7] Developing Novel Therapeutic Strategies to Overcome Ibrutinib Resistance in Mantle Cell Lymphoma
    Lan Pham
    Zhang, Liang
    Tao, Wenjing
    Zhao, Donglu
    Zhang, Hui
    Xie, Jingmeng
    Wang, Jack
    Nomie, Krystle
    Wang, Michael
    BLOOD, 2015, 126 (23)
  • [8] The HSP90-MYC-CDK9 network drives therapeutic resistance in mantle cell lymphoma
    Fangfang Yan
    Vivian Jiang
    Alexa Jordan
    Yuxuan Che
    Yang Liu
    Qingsong Cai
    Yu Xue
    Yijing Li
    Joseph McIntosh
    Zhihong Chen
    Jovanny Vargas
    Lei Nie
    Yixin Yao
    Heng-Huan Lee
    Wei Wang
    JohnNelson R. Bigcal
    Maria Badillo
    Jitendra Meena
    Christopher Flowers
    Jia Zhou
    Zhongming Zhao
    Lukas M. Simon
    Michael Wang
    Experimental Hematology & Oncology, 13
  • [9] The HSP90-MYC-CDK9 network drives therapeutic resistance in mantle cell lymphoma
    Yan, Fangfang
    Jiang, Vivian
    Jordan, Alexa
    Che, Yuxuan
    Liu, Yang
    Cai, Qingsong
    Xue, Yu
    Li, Yijing
    McIntosh, Joseph
    Chen, Zhihong
    Vargas, Jovanny
    Nie, Lei
    Yao, Yixin
    Lee, Heng-Huan
    Wang, Wei
    Bigcal, JohnNelson R.
    Badillo, Maria
    Meena, Jitendra
    Flowers, Christopher
    Zhou, Jia
    Zhao, Zhongming
    Simon, Lukas M.
    Wang, Michael
    EXPERIMENTAL HEMATOLOGY & ONCOLOGY, 2024, 13 (01)
  • [10] Plasma and CSF therapeutic drug monitoring of ibrutinib in patients with CNS dissemination in mantle cell lymphoma (MCL)
    Goldwirt, L.
    Sauvageon, H.
    Madelaine, I.
    Thieblemont, C.
    Mourah, S.
    FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2015, 29 : 49 - 49
12345